Bevacizumab revisited: its use in different mouse models of ocular pathologies (Q35223791)

7 August 2017

title

Bevacizumab revisited: its use in different mouse models of ocular pathologies (English)

1 reference

7 August 2017

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25117905%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Karolien Hollanders

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25117905%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Tine Van Bergen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25117905%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Sarah Van de Velde

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25117905%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Davine Sijnave

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25117905%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Evelien Vandewalle

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25117905%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Ingeborg Stalmans

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25117905%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

publication date

12 August 2014

1 reference

7 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25117905%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25117905%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25117905%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

page(s)

611-621

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25117905%20AND%20SRC:MED&resulttype=core&format=json

Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele

2 June 2020

cites work

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2014.943910

Vascular endothelial growth factor signaling pathways: therapeutic perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2014.943910

The biology of VEGF and its receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2014.943910

VEGF signalling: integration and multi-tasking in endothelial cell biology

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2014.943910

Association of retinal vascular endothelial growth factor with avascular retina in a rat model of retinopathy of prematurity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2014.943910

Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2014.943910

Single nucleotide polymorphism and serum levels of VEGFR2 are associated with age related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2014.943910

Inhibition of vascular endothelial growth factor reduces scar formation after glaucoma filtration surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2014.943910

Inhibition of placental growth factor improves surgical outcome of glaucoma surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2014.943910

Bevacizumab--current status and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2014.943910

The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2014.943910

Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2014.943910

Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2014.943910

Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2014.943910

Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2014.943910

Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2014.943910

Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2014.943910

Interaction between bevacizumab and murine VEGF-A: a reassessment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2014.943910

A new model of experimental choroidal neovascularization in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2014.943910

Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2014.943910

Oxygen-induced retinopathy: a model for vascular pathology in the retina.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2014.943910

Effect of increased oxygen concentration on new vessel growth in the adult cornea

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2014.943910

The mouse retina as an angiogenesis model

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2014.943910

Validation of the Glaucoma Filtration Surgical Mouse Model for Antifibrotic Drug Evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2014.943910

Matrix metalloproteinase-9 contributes to choroidal neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2014.943910

Laser-induced choroidal neovascularization model to study age-related macular degeneration in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2014.943910

Regulation of scar formation by vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2014.943910

AMA0076, a novel, locally acting Rho kinase inhibitor, potently lowers intraocular pressure in New Zealand white rabbits with minimal hyperemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2014.943910

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2014.943910

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2014.943910

Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2014.943910

Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2014.943910

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2014.943910

Serum eyedrops antagonize the anti(lymph)angiogenic effects of bevacizumab in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2014.943910

Evaluation of angiogenesis using micro-computed tomography in a xenograft mouse model of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2014.943910

Bevacizumab accelerates corneal wound healing by inhibiting TGF-beta2 expression in alkali-burned mouse cornea

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2014.943910

Corneal penetration of topical and subconjunctival bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2014.943910

Involvement of SPARC and MMP-3 in the Pathogenesis of Human Pterygium

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2014.943910

Further Pharmacological and Genetic Evidence for the Efficacy of PlGF Inhibition in Cancer and Eye Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2014.943910

10.3109/02713683.2014.943910

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25117905%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25117905%20AND%20SRC:MED&resulttype=core&format=json